Free Trial
→ Elon Reveals Why There Soon Won’t Be Any Money For Social Security (From Colonial Metals) (Ad)
OTCMKTS:BIXT

Bioxytran Q2 2023 Earnings Report

Bioxytran logo
$0.15 -0.01 (-5.66%)
As of 05/29/2025 03:58 PM Eastern
ProfileEarnings History

Bioxytran EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioxytran Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioxytran Announcement Details

Quarter
Q2 2023
Date
7/31/2023
Time
N/A
Conference Call Date
Monday, July 31, 2023
Conference Call Time
10:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Bioxytran's Q2 2023 Press ReleasePress Release
(8-K)
Bioxytran's Q2 2023 Quarterly reportQuarterly report
(10-Q)

Bioxytran Earnings Headlines

Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission
May 21, 2025 | finance.yahoo.com
Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission
May 21, 2025 | globenewswire.com
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
May 30, 2025 | Colonial Metals (Ad)
BIOXYTRAN, INC.: Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
May 12, 2025 | finanznachrichten.de
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
May 12, 2025 | globenewswire.com
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
April 11, 2025 | globenewswire.com
See More Bioxytran Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioxytran? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioxytran and other key companies, straight to your email.

About Bioxytran

Bioxytran (OTCMKTS:BIXT), a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

View Bioxytran Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles